We have located links that may give you full text access.
Shikimic acid prevents cartilage matrix destruction in human chondrocytes.
International Immunopharmacology 2018 October
Abnormal reduction of extracellular matrix (ECM), including type II collagen and aggrecan, caused by tumor necrosis factor-α (TNF-α) is an important pathological feature of osteoarthritis (OA). Shikimic acid (SA), derived from natural plants, has displayed effective pharmacological properties in diverse diseases. The biological roles of SA in OA have not been reported before. Here, we found that treatment with SA (1 mM, 10 mM) prevented TNF-α-induced degradation of type II collagen and aggrecan ECM in human primary chondrocytes culture in vitro. Importantly, we also reported that SA treatment reduced TNF-α-induced expression of matrix metalloproteinase‑1, ‑3, and ‑13 (MMP‑1, ‑3, and ‑13) and increased expression of tissue inhibitor of metalloproteinase‑1 and ‑2 (TIMP‑1, ‑2). Additionally, SA treatment attenuated TNF-α-induced expression of a disintegrin and metalloprotease‑4 and ‑5 (ADAMTS‑4, ‑5). Mechanistically, we found that SA prevented activation of the nuclear factor-κB (NF‑κB) pathway. Our findings suggest that SA might act as an important therapeutic agent in the treatment of OA.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app